The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Atrovent     [(1R,5R)-8-methyl-8-propan-2- yl-8...

Synonyms: Aerodose, Aerovent, Atronase, Ipravent, Apovent, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of N-Isopropylatropine


Psychiatry related information on N-Isopropylatropine

  • After an extensive screening program, 5,887 participants have been randomized to one of three groups: usual care, intervention with smoking cessation and the use of a placebo inhaler, and intervention with smoking cessation and the use of ipratropium bromide [6].
  • RESULTS: Improvement in FEV1 and area under the FEV1 response-time curve from time 0 to 4 h (FEV1AUC0-4) was significantly greater for the combination of albuterol plus ipratropium than either agent alone on all test days [7].

High impact information on N-Isopropylatropine


Chemical compound and disease context of N-Isopropylatropine


Biological context of N-Isopropylatropine


Anatomical context of N-Isopropylatropine

  • Pulmonary effects of sulfur dioxide exposure and ipratropium bromide pretreatment in adults with nonallergic asthma [20].
  • Ipratropium bromide, two sprays (20 micrograms per spray) in each nasal cavity four times daily, for 3 weeks, produced a major reduction in nasal discharge severity and duration (p less than 0.00005 for daytime reduction in both) [21].
  • Unlike ipratropium bromide (100 nM), which dissociated so quickly that there was little difference in the [3H]NMS association, compared with vehicle-treated membranes, Ba 679 BR (1 nM) had a strong protective effect against [3H]NMS binding ( > 70%) that lasted for 90 min [22].
  • Like ipratropium bromide, Ba 679 BR showed no selectivity in its interactions with rat cerebrocortical M1 receptors (labeled with [3H]telenzepine) or heart M2 and salivary gland M3 receptors [labeled with [N-methyl-3H]scopolamine ([3H)] [22].
  • CONCLUSION: Low-dose ipratropium can decrease airway size by the initial, preferential blockade of neuronal M2 muscarinic receptors, whereas a larger dose of ipratropium blocks M3 muscarinic receptors on airway smooth muscle, resulting in bronchodilation [23].

Associations of N-Isopropylatropine with other chemical compounds


Gene context of N-Isopropylatropine


Analytical, diagnostic and therapeutic context of N-Isopropylatropine


  1. The treatment of unrelated disorders in patients with chronic medical diseases. Redelmeier, D.A., Tan, S.H., Booth, G.L. N. Engl. J. Med. (1998) [Pubmed]
  2. Meconium ileus equivalent in association with nebulised ipratropium bromide in cystic fibrosis. Mulherin, D., FitzGerald, M.X. Lancet (1990) [Pubmed]
  3. Paralytic ileus associated with ipratropium. Markus, H.S. Lancet (1990) [Pubmed]
  4. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, double-blind, placebo-controlled trial. Hayden, F.G., Diamond, L., Wood, P.B., Korts, D.C., Wecker, M.T. Ann. Intern. Med. (1996) [Pubmed]
  5. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Bleecker, E.R., Britt, E.J. Am. J. Med. (1991) [Pubmed]
  6. Public screening for lung disease: experience with the NIH Lung Health Study. Owens, G.R. Am. J. Med. (1991) [Pubmed]
  7. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Friedman, M., Serby, C.W., Menjoge, S.S., Wilson, J.D., Hilleman, D.E., Witek, T.J. Chest (1999) [Pubmed]
  8. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. Qureshi, F., Pestian, J., Davis, P., Zaritsky, A. N. Engl. J. Med. (1998) [Pubmed]
  9. Long-term ipratropium bromide nebuliser therapy and lung mucociliary clearance. Pavia, D., Lopez-Vidriero, M.T., Sutton, P.P., Clarke, S.W. Lancet (1982) [Pubmed]
  10. Sputum viscosity and long-term ipratropium bromide nebuliser therapy. Crompton, G.K. Lancet (1982) [Pubmed]
  11. The role of anticholinergics in chronic obstructive pulmonary disease. Barnes, P.J. Am. J. Med. (2004) [Pubmed]
  12. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Braun, S.R., McKenzie, W.N., Copeland, C., Knight, L., Ellersieck, M. Arch. Intern. Med. (1989) [Pubmed]
  13. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Friedman, M. Am. J. Med. (1996) [Pubmed]
  14. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Khoukaz, G., Gross, N.J. Am. J. Respir. Crit. Care Med. (1999) [Pubmed]
  15. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. Boulet, L.P., Turcotte, H., Tennina, S. J. Allergy Clin. Immunol. (1989) [Pubmed]
  16. Bronchial hyperreactivity in patients with familial amyloidotic polyneuropathy and autonomic neuropathy. Kawano, O., Kohrogi, H., Ando, Y., Iwagoe, H., Fujii, K., Hamamoto, J., Yamaguchi, T., Okabe, H., Ando, M. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  17. Hemodynamic and non-bronchial effects of ipratropium bromide. Anderson, W.M. Am. J. Med. (1986) [Pubmed]
  18. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Rodrigo, G., Rodrigo, C., Burschtin, O. Am. J. Med. (1999) [Pubmed]
  19. Clinical pharmacology and toxicology of ipratropium bromide. Cugell, D.W. Am. J. Med. (1986) [Pubmed]
  20. Pulmonary effects of sulfur dioxide exposure and ipratropium bromide pretreatment in adults with nonallergic asthma. McManus, M.S., Koenig, J.Q., Altman, L.C., Pierson, W.E. J. Allergy Clin. Immunol. (1989) [Pubmed]
  21. Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide. Dolovich, J., Kennedy, L., Vickerson, F., Kazim, F. J. Allergy Clin. Immunol. (1987) [Pubmed]
  22. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Haddad, E.B., Mak, J.C., Barnes, P.J. Mol. Pharmacol. (1994) [Pubmed]
  23. Ipratropium decreases airway size in dogs by preferential M2 muscarinic receptor blockade in vivo. Groeben, H., Brown, R.H. Anesthesiology (1996) [Pubmed]
  24. Ipratropium bromide in chronic bronchitis/emphysema. A review of the literature. Lakshminarayan, S. Am. J. Med. (1986) [Pubmed]
  25. Effect of ipratropium bromide on airway mucociliary function. Wanner, A. Am. J. Med. (1986) [Pubmed]
  26. Use of ipratropium bromide in asthma. Results of a multi-clinic study. Storms, W.W., Bodman, S.F., Nathan, R.A., Busse, W.W., Bush, R.K., Falliers, C.J., O'Hollaren, J.D., Weg, J.G. Am. J. Med. (1986) [Pubmed]
  27. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Campbell, S. Arch. Intern. Med. (1999) [Pubmed]
  28. Combination bronchodilator therapy in asthma. Ruffin, R.E., McIntyre, E., Crockett, A.J., Zielonka, K., Alpers, J.H. J. Allergy Clin. Immunol. (1982) [Pubmed]
  29. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Colice, G.L. Am. J. Med. (1996) [Pubmed]
  30. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Tashkin, D.P., Ashutosh, K., Bleecker, E.R., Britt, E.J., Cugell, D.W., Cummiskey, J.M., DeLorenzo, L., Gilman, M.J., Gross, G.N., Gross, N.J. Am. J. Med. (1986) [Pubmed]
  31. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Braun, S.R., Levy, S.F. Am. J. Med. (1991) [Pubmed]
  32. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. Kaiser, H.B., Findlay, S.R., Georgitis, J.W., Grossman, J., Ratner, P.H., Tinkelman, D.G., Roszko, P., Zegarelli, E., Wood, C.C. J. Allergy Clin. Immunol. (1995) [Pubmed]
  33. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Anthonisen, N.R., Connett, J.E., Kiley, J.P., Altose, M.D., Bailey, W.C., Buist, A.S., Conway, W.A., Enright, P.L., Kanner, R.E., O'Hara, P. JAMA (1994) [Pubmed]
  34. Ipratropium bromide nebulizer therapy and airway submucosal gland secretion. Nadel, J.A. Lancet (1982) [Pubmed]
WikiGenes - Universities